CHRYSO®Quad: A Range of Admixtures and Services for Complex Local Sands and Aggregates, in Support of the Circular Economy
20.4.2023 12:20:00 EEST | Business Wire | Press release
To support sustainable construction stakeholders, CHRYSO is strengthening its CHRYSO®Quad range and associated services in response to the challenges of the circular economy. CHRYSO promotes the use of complex aggregates sourced locally or from recycled concrete from deconstruction sites.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230418005807/en/
CHRYSO®Quad fosters local sourcing of aggregates and sands (Photo: Shutterstock)
Dedicated services to characterize materials and adjust admixture solutions
It all starts with the analysis of sands using the patented CHRYSO®CLEAR Test method, which diagnoses the presence of swelling clay. Then, the dedicated CHRYSO®Quad Lab service allows CHRYSO experts to carry out a precise diagnosis of a series of additional parameters: particle size (to determine the lack or excess of fines), absorption, shape factors, etc.
Additionally, compaction tests are performed in CHRYSO's application laboratories to consider all the parameters of the concrete mix design. Finally, the brand-new digitalized service CHRYSO®Quad App proposes the most suitable admixture solution based on the customer's material characterization (sands and aggregates) and thus broadens the scope of potential supply sources.
The use of complex aggregates and sands while improving concrete performance
The customized CHRYSO®Quad admixture solutions are adjusted according to the available resources of complex sands and aggregates. This allows clients to gain flexibility by integrating new sands and aggregates into their concrete mix and overcome shortages or tensions in material supplies. CHRYSO experts accompany their clients in producing durable and robust concrete that can withstand material variations.
CHRYSO®Quad contributes to the circular economy and reduces the carbon footprint
By anticipating the constraints of quality and availability of local sands and aggregates, CHRYSO®Quad fully embraces a circular economy approach.
CHRYSO®Quad is a development lever for recycling materials from deconstruction, allowing for the recovery and use of recycled aggregates.
The use of local resources also contributes to reducing supply costs and decreasing the carbon footprint associated with the transportation of raw materials.
CHRYSO continues to deploy CHRYSO®Quad
To date, 9 million m3 of concrete have already benefited from CHRYSO®Quad solutions, including on large construction sites around the world. Leveraging its international network of application laboratories, CHRYSO provides answers to the sourcing challenges of aggregates faced by industry stakeholders.
CASE STUDY
With CHRYSO®Quad 870, a concrete industry player manages to use 100% of complex sands in its concrete formulation
To support a client in the south of France in optimizing the sand resources used in its concrete formulation, CHRYSO proposed its CHRYSO®Quad 870 solution, which improved productivity, concrete quality, and allowed for sourcing exclusively from local suppliers.
This industry player supplied his plant with sand from two quarries. A complex crushed sand, sourced from a quarry near the plant. A second "corrective" sand, from another quarry located 60km from the plant. Up to 50% of each sand was used in the different concrete mixes, which ranged from class S3 to S5.
In its specifications, the industry player requested that CHRYSO provides a solution to increase its capacity to use complex sands (with a high content of fines and the presence of clays). Thanks to the CHRYSO®Quad Lab service, sands were recovered and analyzed in the laboratory and in the plants. This allowed CHRYSO to design the customized CHRYSO®Quad 870 product. The first product testing phases were validated on site by sand variability checks carried out by the client using the CHRYSO®CLEAR Test kit.
As a result, the customer has extended the use of CHRYSO®Quad 870 to three other concrete plants and now uses 100% complex sand from a local quarry. The use of a single sand, with a constant dosage, brings a benefit of regularity in the production, reducing the weight of CEM II A cement in the design mix, which represents a 10% reduction of the carbon footprint. In addition, thanks to the exclusive use of short-distance sourcing, 24 lorry journeys per month have been avoided.
ABOUT SAINT-GOBAIN CONSTRUCTION CHEMICALS
Saint-Gobain Construction Chemicals offers cement additives, concrete admixtures and specialty building materials, through the combined activities of Chryso and GCP. Its recent technologies for sustainable construction help reduce energy consumption, lower the carbon footprint of cements and concrete, and foster the circular economy. Leveraging its global manufacturing presence, Saint-Gobain Construction Chemicals serves its customers through local sites in over 40 countries, employing over 2,700 people.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230418005807/en/
Contact information
Press relations
CHRYSO
Daphnée DECAUDIN
Daphnee.decaudin@chryso.com
+33 6 19 07 64 74
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
